Clinipace Worldwide’s Ran Frenkel Promoted to Managing Director, EMEA

The Associated Press

MORRISVILLE, N.C.--(BUSINESS WIRE)--Dec 13, 2012--Clinipace Worldwide, a global digital contract research organization (dCRO), today announced company executive, Ran Frenkel, RPh, Vice President, International Business Development, will take on additional responsibility as the Managing Director, EMEA. Country managers in the region will report directly to Frenkel in his new role.

Frenkel joined the Clinipace Worldwide team in May 2011 through the company’s acquisition of Swiss-based PFC Pharma Focus (PFC). He has served the company for over seven years, helping to establish the Israel office, and is now poised to lead EMEA operations from the European headquarters in Zurich.

“Ran has consistently demonstrated that he understands and supports our corporate vision of driving innovation in clinical research through a technology-amplified service platform,” said Jeff Williams, CEO, Clinipace Worldwide. “Ran is committed to extending our unique approach to service delivery throughout EMEA, and I’m confident he will continue to lead our growth in the region.” Original PFC founders, Kurt Pfister, PhD, CEO, European Operations, and Kathryn Voegeli, PhD, COO, European Operations, are stepping down from day-to-day management roles. They will remain with Clinipace Worldwide through 2013 in an advisory capacity and will remain on the Board of Directors of Clinipace AG (the company’s European entity).

“Clinipace is proud of the leadership demonstrated by both Kurt and Kathryn in growing the company’s presence and foothold in EMEA,” said Williams. “They helped build a talented team of experts, and as a combined company for the past two years, our common goals have been easily achieved.” See related: Clinipace Worldwide’s Ran Frenkel Elected to IISRA Board of Directors Clinipace Worldwide Celebrates 20 Years of Service in Europe Clinipace Worldwide Acquires Switzerland-Based PFC Pharma Focus Ltd. About Clinipace Worldwide As a global full-service digital contract research organization (dCRO), we have pioneered an innovative technology-amplified CRO service model to serve the unique needs of venture-backed, mid-tier, and strategic pharmaceutical, biotechnology, and medical device firms. Powered by TEMPO™, our proprietary eClinical platform, our team of experts brings extensive therapeutic knowledge and insight into assisting life science firms in developing and executing regulatory strategies, clinical development, and post-approval research to ensure a successful drug and medical device development program. We have managed over 1,200 global clinical research, strategic product development, regulatory, and GxP/CMC/QA projects in therapeutic areas such as cardiovascular & metabolic diseases, central nervous system, dermatology, gastroenterology, immunology, infectious diseases, nephrology, oncology, respiratory, rheumatology, and vaccines (and other cell and tissue based therapies).

Clinipace Worldwide is headquartered in Research Triangle Park, North Carolina with offices in Irvine (CA), Boulder (CO), Overland Park (KS), Zurich (CH), Munich (DE), High Wycombe (UK), Tel-Aviv (IL), Sao Paulo (BR), Buenos Aires (AR), Trivandrum Kerala (IN) and New Delhi (IN). For more information, visit our website at www.clinipace.com.

CONTACT: For Clinipace Worldwide Molly Thompson, 919-821-2822 mthompson@crossroadspr.com KEYWORD: UNITED STATES EUROPE NORTH AMERICA NORTH CAROLINA MIDDLE EAST ISRAEL INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL RESEARCH SCIENCE SOURCE: Clinipace Worldwide Copyright Business Wire 2012 PUB: 12/13/2012 09:30 AM/DISC: 12/13/2012 09:30 AM http://www.businesswire.com/news/home/20121213005353/

Source URL (retrieved on *03/10/2014 - 10:47pm*):
http://www.mdtmag.com/news/2012/12/clinipace-worldwide%E2%80%99s-ran-frenkel-promoted-managing-director-emea?qt-recent_content=0